Activation of Lipoxin A₄ Receptors by Aspirin-triggered Lipoxins and Select Peptides Evokes Ligand-specific Responses in Inflammation

By Nan Chiang, Iolanda M. Fierro, Karsten Gronert, and Charles N. Serhan

From the Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115

Abstract

Lipoxin (LX) A₄ and aspirin-triggered LX (ATL) are endogenous lipids that regulate leukocyte trafficking via specific LXA₄ receptors (ALXRs) and mediate antiinflammation and resolution. ATL analogues dramatically inhibited human neutrophil (polymorphonuclear leukocyte [PMN]) responses evoked by a potent necrotactic peptide derived from mitochondria and a rogue synthetic chemotactic peptide. These bioactive lipid analogues and small peptides each selectively competed for specific [³H]-LXA₄ binding with recombinant human ALXR, and its N-glycosylation proved essential for peptide but not LXA₄ recognition. Chimeric receptors constructed from receptors with opposing functions, namely ALXR and leukotriene B₄ receptors (BLTs), revealed that the seventh transmembrane segment and adjacent regions of ALXR are essential for LXA₄ recognition, and additional regions of ALXR are required for high affinity binding of the peptide ligands. Together, these findings are the first to indicate that a single seven-transmembrane receptor can switch recognition as well as function with certain chemotactic peptides to inhibitory with ATL and LX (lipid ligands). Moreover, they suggest that ALXR activation by LX or ATL can protect the host from potentially deleterious PMN responses associated with innate immunity as well as direct effector responses in tissue injury by recognition of peptide fragments.

Key words: inhibitory receptors • antiinflammation • resolution • leukocytes • MHC binding peptide

Introduction

Acute inflammation is normally a localized protective response where neutrophils (PMNs) play a pivotal role not only to destroy invading microbes but also to wall off injured tissues (1). Endogenous chemical mediators generated by the host govern leukocyte trafficking from the vasculature to active sites (2), and in this context leukotriene B₄ is among the most potent PMN chemoattractants known (3–5). Excessive acute inflammation caused by aberrant host recognition or prolonged activation of effector cells such as PMNs can release an array of proinflammatory mediators amplifying diverse cellular responses that acutely can give rise to reperfusion injury as well as chronic inflammatory diseases such as rheumatoid arthritis (6, 7). Most lipid mediators, including eicosanoids (prostaglandins and leukotrienes), elicit inflammation and vascular events and thus are held to be potent proinflammatory mediators (3). Recent results provide evidence for a new appreciation that certain lipoxigenase-derived eicosanoids possess potent “anti-PMN” actions and antiinflammatory properties (7–10). In particular, lipoxin (LX) A₄ and recently identified aspirin-triggered LX A₄ (ATL, endogenous 15-epimer of LXA₄) exhibit anti-inflammatory properties and appear to serve as novel endogenous “stop signals” to regulate excessive leukocyte trafficking and possibly deleterious responses of PMNs (7).

1Abbreviations used in this paper: ALXR, lipoxin A₄ receptor; ATL, aspirin-triggered 15-epi-LXA₄; ATLₐ, ATL analogue(s) [ATL₁: 15(R/S)-methyl-LXA₄ methyl ester; ATL₂: 15-epi-16-(para-fluoro)-phenoxy-LXA₄ methyl ester]; BLT, leukotriene B₄ receptor; CHO, Chinese hamster ovary; FPR, N-formyl peptide receptor; HEK, human embryonic kidney; LX, lipoxin; LXA₄, 5(S),6(R),15(S)-trihydroxy-7,9,13-trans-eicosatetraenoic acid; SAA, serum amyloid protein A.
Aspirin is widely used for its antiinflammatory and analgesic properties (11) and also exhibits newly recognized beneficial actions, including prevention of cardiovascular diseases and decreasing the incidence of lung, colon, and breast cancers (12). In addition to inhibiting formation of both prothrombotic and proinflammatory eicosanoids, aspirin-acylated cyclooxygenase 2 remains active, and upon cell activation initiates the endogenous generation of anti-inflammatory 15-epi-LXA4 (15R-LXA4, ATL) (7). Like other local mediators, LXA4 and ATL are rapidly generated within seconds to minutes, act locally to evoke cellular responses, and are rapidly inactivated by further metabolism. Hence, LXA4 and ATL stable analogues (ATLa) were designed that resist rapid enzymatic inactivation and prolong their duration of action. These analogues display potent anti-PMN actions in vitro and in vivo (7, 13-15) and act via mechanisms that bypass aspirin's unwanted side effects (gastric bleeding, etc.), since they act directly on leukocytes (7) and regulate a cytokine–chemokine axis (16). In this report, we used these new molecular tools (e.g., LXA4 and ATLa, structures shown in Fig. 1) and found a novel mechanism for PMN s in host recognition and evidence for a unique functional switch to endogenous antiinflammatory programming.

LXA4 and its carbon-15 epimeric counterpart ATL (e.g., 15-epi-LXA4) regulate leukocyte responses via interacting with high affinity (Kd ~ 0.5 nM) to a G protein–coupled receptor denoted ALXR (17; for a review, see reference 7). This receptor is related at the nucleotide sequence level to both chemokine and chemotactic peptide receptors, such as N-formyl peptide receptor (FPR) (5). However, we (18) and others (19) found that the ALXR does not effectively respond to formyl peptide FMLP, unless cells are exposed to higher pharmacological doses (i.e., >1-10 μM), suggesting that these are not physiologically relevant ligands. Along these lines, the nonclassical MHC Ib CD1b and presents both peptides (20) and lipid antigens such as the long chain fatty acid, mycotic acid, found in mycobacteria (21). Thus, T cells can recognize a broader array of both peptide and lipid antigens than previously appreciated. In view of the diversity of T cell recognition, it was of interest to determine whether effector cell (i.e., PMN) receptors for antiinflammatory lipid mediators (13), namely ALXR, could also utilize specific non-lipid-derived ligands.

**Materials and Methods**

**Materials.** The MHC binding peptide (MYFINILTL) and M-MK-1 peptide (LESIFFR SLLFRVM) were prepared by custom synthesis at Research Genetics, Inc. (125). MHC binding peptide was prepared by Phoenix Pharmaceuticals, Inc. and purified by HPLC. The oligonucleotides were synthesized by Integrated DNA Technologies, Inc. DNA sequence analysis was performed in the Brigham and Women's Hospital DNA Sequencing Core. Restriction enzymes were purchased from Roche Molecular Biochemicals with the exception of EcoNI, which was from New England Biolabs.

**Cloning and Plasmid Construction.** The pcDNA3-BLT plasmid containing human leukotriene B4 receptor (BLT)2 cDNA was prepared as described (15). ALXR cDNA was used as described (17), and BLT-ALXR chimeric receptors were constructed by PCR and restriction digestion. In brief, for B/A254, ALXR cDNA fragment (796–1055) carrying EcoNI and XhoI sites on 5' and 3' ends, respectively, was obtained by PCR (30 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min) using Taq DNA polymerase (Qiagen) with oligonucleotides 5'-gtgcgcggcggctttgtgggccaagactt-3' and 5'-ctttcttgagtcacattgcctgtaac-3', respectively. PCs-EcoNI and XhoI (New England Biolabs) and ligated into EcoNI and XhoI sites in pcDNA3-BLT plasmid. The other chimeras were constructed using this procedure with the oligonucleotides and restriction enzymes listed in Table I. Each resulting construct was verified by complete DNA sequence analysis.

**Cell Culture and Transfection.** Human embryonic kidney (HEK) 293 and Chinese hamster ovary (CHO) cells (American Type Culture Collection) were cultured in DMEM and HAM F-12 medium (BioWhittaker), respectively, supplemented with 10% fetal bovine serum. Cells were transfected with plasmid DNA (5 μg) using SuperFect reagent (QIAGEN). After 48 h, cells were placed in DMEM or HAM F-12 with 0.4 mg/ml Geneticin.
Preparation of [11,12-\(\text{\textsuperscript{3}}\text{H}\)-LXA\(_4\)]; [11,12-\(\text{\textsuperscript{3}}\text{H}\)-LXAs]-methyl ester was prepared in collaboration with Schering AG (Berlin, Germany) using acetylenic-LXAs-methyl ester precursor (prepared with Dr. Nicos A. Petasis, Department of Chemistry, University of Southern California, Los Angeles, CA) essentially as reported (22) and was a gift from Dr. H.D. Perez at Berlex Biosciences (Richmond, CA). [11,12-\(\text{\textsuperscript{3}}\text{H}\)-LXAs]-methyl ester was purified in this laboratory using a Hewlett Packard 1100 Series diode array detector (DAD) equipped with a binary pump and eluted on a Beckman Ultrasphere C18 column (250 x 4.5 mm, 5 \(\mu\)m) using a mobile phase composed of methanol/water/acetate (60:39.99:0.01, vol/ vol/ vol; flow rate 1.0 ml/min) as phase 1 (0–15 min), a linear gradient (0–30%) with methanol/acetate (99:99.99:0.01, vol/ vol/ vol) as phase 2 (15–55 min), and a linear gradient (30–100%) of methanol/acetate (99:99.01:0.01, vol/ vol/ vol) as phase 3 (55–60 min). To minimize chemical degradation of [11,12-\(\text{\textsuperscript{3}}\text{H}\)-LXAs]-methyl ester after HPLC chromatography, the mobile phase was removed under a stream of N\(_2\), suspended in ethanol, and used immediately for binding experiments.

Results and Discussion

R esults in Fig. 2 demonstrate that the mitochondria peptide fragment MYFINILTL (structures shown in Fig. 1) derived from NADH dehydrogenase subunit 1 (ND1) directly stimulated PMN chemotaxis. This peptide binds to MHC class I b molecule H2-M3 in formylated as well as nonformylated forms (25), and thus is denoted as MHC binding peptide. It is of interest because mitochondria-derived peptides, including N D1 peptides, are held to be liberated from mitochondria and may play a role in accumulation of phagocytic cells during tissue and cell lysis that can accompany bacterial infection and/or ischemia–reperfusion injury (26). This peptide gave a chemotaxis response at concentrations as low as 1 nM (Fig. 2 A). The metabolically stable analogue of LXAs and ATL (15(R)/(S))-methyl-LXAs [ATLa\(_4\)], structure shown in Fig. 1), which resists rapid enzyme inactivation (27) at equimolar concentration to the peptide, dramatically inhibited the MHC peptide–stimulated chemotaxis by \(\approx 85\%\) (Fig. 2 B). This lipoxin analogue has structural properties of both LXAs and ATL, and alone at 10 nM did not induce chemotaxis (Fig. 2 A).

We also tested the synthetic surrogate peptide MMK-1 (LESIFR SLLFRVM, structure shown in Fig. 1) that was recently reported to mobilize Ca\(^{2+}\) via ALX R (previously named FPR L-1; reference 28). This peptide also stimulated PMN chemotaxis that peaked at 10 nM (Fig. 2 A) and was inhibited by ATLa\(_4\) (\(\approx 78\%), Fig. 2 B). Both the MHC binding peptide and MMK-1 peptide activated PMNs as monitored by microphysiometry, evoking a response consistent with receptor-initiated increases in extracellular acidification rates (Fig. 3, inset). Each peptide gave distinct profiles. The lipid ATL stable analogue 15-epi-16-(para-fluoro)-phenoxy-LXAs (ATLa\(_4\), structure shown in Fig. 1) did not increase the extracellular acidification rates of PMNs but clearly blocked both MHC binding peptide- and MMK-1–enhanced responses (Fig. 3). Hence, both peptides evoke PMN responses that were blocked by ATL.

To examine whether the MHC binding peptide shares recognition sites with LXAs and ATL on PMNs, \(\text{\textsuperscript{3}}\text{H}\)-LXAs was prepared (22; see Materials and Methods) for direct ligand binding and competition. Of interest, MHC binding peptide and MMK-1 directly competed with \(\text{\textsuperscript{3}}\text{H}\)-LXAs (IC\(_{50}\) < \(10^{-9}\) M) (see below) but not \(\text{\textsuperscript{3}}\text{H}\)-LTB\(_4\) binding on human PMNs (data not shown). To examine the direct binding of this peptide with PMNs, an \(\text{\textsuperscript{125}}\text{I}\)-labeled MHC binding peptide was prepared by iodination at the Tyr residue. However, the \(\text{\textsuperscript{125}}\text{I}\)-labeled peptide did not promote PMN chemotaxis, nor did it show specific binding (n = 3, data not shown), suggesting that the iodination altered
MHC binding peptide recognition on PMNs. Together, these findings suggest that LXA₄/ATL and these peptides share common recognition sites on PMNs, yet the peptides evoke PMN responses distinct from those observed with the lipid ligands.

ATL analogues are potent inhibitors of TNF-α–initiated PMN infiltration into murine dorsal air pouch when administered either by topical intra–air pouch or systemic intravenous delivery (14). In this model, administration of murine TNF-α induces a time-dependent increase in the levels of macrophage inflammatory protein 1α, macrophage inflammatory protein 2, and JE (the human homologue of macrophage chemotaxis protein 1) in the pouch exudate (29). The steady state mRNA levels of these chemokines are also increased in exudate cells as well as in the tissue that lines the air pouch. Hence, the initial phase of exudate formation and leukocyte infiltration in this model (29) appears to be predominantly chemokine driven. To test whether the synthetic peptide MMK-1 shares this inhibitory property, it was evaluated for its ability to impact exudate formation and leukocyte trafficking in the murine air pouches and directly compared with the action of LX. When injected locally into the air pouch, the lipid mediator analogue ATLₐ₁ (10 μg/pouch) profoundly inhibited PMN trafficking into these sites (~50%, P = 0.03; Fig. 4 A). In sharp contrast, the MMK-1 peptide at equal amounts (10 μg/pouch) did not give a statistically significant inhibition (Fig. 4 A) and, moreover, neither the synthetic peptide (MMK-1) (Fig. 4 A) nor lipid-derived mediator (16) given alone at 10 μg per pouch stimulated PMN infiltration. At much higher concentrations (e.g., 100 μg/pouch), we noted that MMK-1 gave statistically significant PMN infiltration (Fig. 4 B, P = 0.04). Together, these findings indicate that ATL and MMK-1, although sharing common recognition sites on PMNs, each displayed distinct actions for controlling PMN trafficking in vivo.

To address the question of whether ATL as well as synthetic peptides directly bind to recombinant ALX R, we examined their ability to compete for specific ³H-LXA₄ or ³H-LTB₄ binding in HEK293 cells stably expressing either human ALXR or human BLT (4, 15). Bioavailable stable analogues of the lipid mediators LXA₄ and ATL (e.g., ATLₐ₁ and ATLₐ₂) that exhibit potent anti-PMN actions in vivo (7) competed for specific binding of ³H-LXA₄ in ALXR–transfected HEK293 cells (Fig. 5 A), with IC₅₀ = 10⁻¹¹ to 10⁻¹⁰ M, which exceed by >1,000-fold that of a structurally related but biologically inactive isomer, 15-deoxy-LXA₄. The absence of a carbon-15 alcohol in LXA₄
and ATL results in essentially a biologically inactive product (see reference 27) (IC$_{50}$ $\approx$ 10$^{-7}$ M). These findings indicate that the 15-hydroxyl group of LXA$_4$ is important for receptor recognition (Fig. 5A).

Of interest, both the MHC binding peptide and MMK-1 competed for specific binding of $^3$H-LXA$_4$ at a level comparable to the inhibitory lipid ligands (IC$_{50}$ $\approx$ 10$^{-11}$ M). These results with MHC binding peptide and MMK-1 demonstrate the direct interaction of these selective peptides with ALXR (Fig. 5B). For purposes of direct comparison, serum amyloid protein A (SAA), a proteolytic product of the acute phase response (30), which was recently shown to stimulate Ca$^{2+}$ mobilization and migration of HFK293 cells expressing ALXR/FPR-L (31), also displaced specific $^3$H-LXA$_4$ binding. However, SAA required a higher amount to achieve significant competition, with an IC$_{50}$ of 10$^{-8}$ to 10$^{-7}$ M (Fig. 5B). These peptide ligands were selective for ALXR, as peptides of random sequence did not compete for $^3$H-LXA$_4$ binding with ALXR (data not shown). Along these lines, the bacterial chemotactic surrogate peptide FMLP did not show displacement of $^3$H-LXA$_4$ binding with ALXR expressed in CHO cells at levels $<$1 $\mu$M (18). Neither LXA$_4$ nor these peptides competed for $^3$H-LTB$_4$ specific binding to BLT, a related G protein–coupled receptor (4), with BLT-transfected HFK293 cells (data not shown). Taken together, these findings provide the first direct evidence that ATL as well as both the MHC binding peptide and MMK-1 specifically interact with recombinant ALXR.

Because both MMK-1 peptide and ATL competed at the same receptor, it was of interest to determine whether they could evoke cellular responses via recombinant ALXR. To this end, we examined chemotaxis in CHO cells expressing ALXR together with Gqo chimera. MMK-1 at 1 nM gave a clear chemotaxis response when compared directly to chemotaxis stimulated by another peptide, FMLP, with CHO cells expressing its cognate receptor, the FPR (Fig. 6). FMLP stimulates CHO cell chemotaxis with FPR (32) and was used here for the purpose of direct comparison. FMLP did not stimulate chemotaxis with ALXR (not shown). ATL at higher concentra-
In CHO cells, ATLa-stimulated chemotaxis is likely the result of different intracellular signaling events that follow ALXR activation by ATLa in CHO cells versus PMNs. In this context, it is of interest to point out that the same ligand–receptor interaction (i.e., ALXR) in human monocytes stimulates chemotaxis (33), as PMN responses are inhibited. In the present experiments, ATLa at 10 nM did not evoke significant chemotaxis (data not shown) but clearly diminished MMK-1-stimulated chemotaxis (>80%) with CHO-ALXR cells (Fig. 6, P < 0.01). This inhibition proved to be ALXR dependent, and together these results indicated that both MMK-1 and ATLa can activate the same recombinant ALXR expressed in CHO cells.

Many G protein-coupled receptors contain N-glycosylation sites, and these sites are also present in ALXR at the NH2 terminus (Asn-4) and second extracellular loop (Asn-179) (17). Carbohydrate moieties of glycoprotein are important for processes such as intracellular trafficking and surface expression. Both bacterial (Listeria monocytogenes) and viral (retrovirus, herpes simplex virus) infection interfere with normal N-glycosylation of the host cells (34–36). Therefore, it was of interest to access the contribution of N-glycosylation of ALXR to ligand class recognition. Results in Fig. 7 demonstrate that deglycosylation of ALXR with N-glycosidase F (from Flavobacterium meningosepticum) treatment of ALXR-transfected HEK293 cells did not dramatically alter LXA4 recognition, as LXA4 competes for 3H-LXA4 binding with deglycosylated ALXR at a level (IC50 ~ 10^{-11} M) comparable to that for native ALXR. In contrast, both MHC binding peptide and MMK-1 peptides displayed an ~3 log order lower affinity (IC50 ~ 10^{-8} M) for the deglycosylated form of ALXR compared with the native ALXR (see Fig. 5 B and Fig. 7). These results indi-
Figure 6. ATLa1 as well as surrogate MMK-1 peptide evoke chemotaxis via ALXR. CHO-FPR or CHO-Gqo-ALXR cells were pretreated with vehicle alone (white, hatched, and black bars, respectively) or ATLa1 (10 nM, gray bar) for 30 min at 37°C and added to the upper compartment of a microchamber (5 × 10⁴/well). Chemotaxis was initiated by addition of FMLP (10 nM, white bar), ATLa1 (100 nM, hatched bar), or MMK-1 (1 nM, black and gray bars) to the lower compartment. Data were expressed as percent chemotaxis above vehicle control. FMLP-evoked chemotaxis in CHO-FPR is considered as 100%. Data represent the mean ± SEM from n = 3 (*p < 0.01).

Figure 7. Deglycosylation of human ALXR attenuates ligand recognition for peptides but not LXA4. Human ALXR-transfected HEK293 cells (5 × 10⁵/ml) were pretreated with glycosidase F (1 U/ml) for 24 h at 37°C and then incubated with 3H-LXA4 for 30 min at 4°C in the presence of an increasing concentration of unlabeled LXA4 (■), MMK-1 (△), or MHC binding peptide (○). Bound and unbound radioligands were separated by filtration and specific binding was determined. Data represent the mean ± SEM from n = 3.

cate that N-glycosylation of ALXR is a key component for peptide but not LXA4 recognition. It is likely that the presence of carbohydrates on this receptor favors the thermodynamics and flexibility that enable recognition of these specific peptides. Taken together, it is possible to envision that the N-glycosylation state of the ALXR can determine ligand binding in vivo and thus can potentially regulate functional responses of leukocytes during microbial challenge or cell injury and contribute to inflammation resolution.

To evaluate the contributions of the major domains of ALXR in interacting with either lipid mediators or peptide ligands, chimeric receptors were constructed with human ALXR and the recently cloned human BLT (4). ALXR and BLT were selected for these chimeric constructs because leukotriene B₄ is a potent chemoattractant (3), a “go” signal, and LXA₄ is an endogenous “stop” signal (7) that inhibits neutrophil chemotaxis, each by their interaction with their specific responsive G protein-coupled receptors. Four chimeric constructs with major domain exchange were prepared (see Table II). The expression levels of these chimeras were similar to those of wild-type receptors as determined by reverse transcription PCR (data not shown). One chimeric receptor, denoted B/A₂₉₉, with COOH terminus of BLT replaced by the corresponding region of ALXR, demonstrated threefold increase (Bₘₐₓ ∼ 30,000 sites/cell) of specific ³H-LTB₄ binding compared with wild-type BLT (Bₘₐₓ ∼ 9,600 sites/cell; cloned in this laboratory using published DNA sequences [4]). Of interest, this chimera gave a 60% decrease in extracellular acidification rate responses compared with wild-type BLT (n = 3), suggesting that the COOH terminus of BLT is important for BLT signaling. In addition, the chimera denoted B/A₂₅₄ displayed specific binding with ³H-LXA₄ with an affinity comparable to that for wild-type ALXR (IC₅₀ ∼ 10⁻¹¹ M; Fig. 8, B and C). This chimera B/A₂₅₄, encompassing the third extracellular loop, seventh transmembrane domain, and COOH terminus of BLT that were replaced by the corresponding regions of ALXR (see sequences in Fig. 8 A and illustration in Fig. 8 B, inset), failed to specifically bind to ³H-LTB₄. Of interest, B/A₂₅₄ showed decreased affinity to both MHC binding peptide and MMK-1 (IC₅₀ ∼ 10⁻⁹ M; Fig. 8 C). Taken together, these results indicate that the third extracellular loop as well as the seventh transmembrane domain are essential for ligand–receptor interaction for ALXR and BLT.

ALXR shares ~70% homology in deduced amino acid sequences with FPR (5, 17) and ~30% homology to the BLT (see reference 4). The murine ALXR was identified and cloned from the stimulated IL-2⁺ NFS strain (13). However, this receptor only binds ³H-FMLP with low affinity (Kᵩ ∼ 5 μM) and is selective for ³H-LXA₄ by 3 log orders of magnitude (18, 19). In addition, FMLP did not compete for ³H-LXA₄ binding with ALXR unless 1–100 μM was used (18). The first extracellular loop and its adjacent transmembrane domains of N-formyl peptide receptors were found to be essential for high affinity FMLP binding as demonstrated by site-directed mutagenesis (37).
as well as FPR-ALXR chimeric receptors (38). For protein-coupled receptors of lipid mediators such as cyclooxygenase products prostaglandin E2 and thromboxane A2, the seventh transmembrane domain of their respective receptors is important for ligand-receptor interactions (39). In view of these results, together with our findings, it is likely that certain natural peptides and endogenous lipid ligands can share a common receptor, exemplified here by results with the ligand requirements for interacting with the receptor that were different for lipid versus peptide ligand recognition.

Recently, SAA was reported to stimulate ALXR-dependent responses in vitro, but required high concentration (i.e., micromolar) to evoke responses (31). Compared with LXs which act at <10⁻⁹ M (13, 17, 18), the structural features that underlie the mimicry are of interest since their IC₅₀ are much higher than the peptides or ATL/LX. ¹²⁵I-SAA displayed specific binding on monocytes and HEK 293 cells, expressing ALXR with apparent Kᵣ of 45 and 64 nM, respectively (31). These values, by comparison, are 1-2 log orders of magnitude higher than those obtained with human PMN and CHO cells expressing ALXR, which gave high affinity binding for ³H-LXA₄ with Kᵣ at 0.5 and 1.7 nM, respectively (see references 13, 17, 18, and 40). These values for LXA₄ are consistent with those obtained in the present experiments with HEK 293 cells stably expressing human ALXR (Fig. 5).

Of interest, SAA levels in peripheral blood are increased as much as 1,000-fold during inflammatory disorders (30), and SAA, given its hydrophobicity, associates with high density lipoproteins when levels exceed 1,000-fold basal values (41). Unlike lipid mediator autacoids such as LXA₄ that are rapidly (seconds to minutes) generated within local sites of inflammation and act within these microenvironments (7), SAA is biosynthesized predominantly in hepatocytes and is released to peripheral blood where its levels slowly elevate and persist for hours to days during an inflammatory response. However, its function during the acute phase and in inflammation remains to be determined (30). In this regard, it is of interest that SAA inhibits the oxidative burst response with N-formyl peptide-stimulated PMNs (42), suggesting that SAA can, like LX and ATL (7), counteract PMN responses to cytokines or bacterial products (7, 14, 16, 42). Thus, the relevance in vivo of SAA in controlling PMN responses via interactions with ALXR remains to be established.

The F-peptide representing the V4-C4 region of HIV-1 envelop protein gp120 is also reported to activate ALXR expressing HEK 293 cells, as monitored by the agonist promoting Ca²⁺ mobilization and chemotaxis. However, there too the HIV-1 F-peptide only gives apparent EC₅₀ values in the micromolar range, yet subsequently downregulates expression and function of CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) in monocytes (43). In this regard, the actions of LXA₄ interaction at this receptor are directly opposite when monocytes and PMNs are exposed to these ligands in vitro (7, 27, 33) and in vivo (16) and require much lower concentrations for recognition and activation. LXA₄ and its analogues stimulate monocyte adherence via ALXR.

### Table II. Ligand Binding Properties of Recombinant ALXR, BLTR, and Chimeric Receptors

| chimera   | BLTR | ALXR | A₅₅/B | B/A₆₂-26₂/B | B/A₂₅₄ | B/A₂₉₉ |
|-----------|------|------|-------|-------------|--------|--------|
| [³H]-LTB₄ |      |      |       |             |        |        |
| Kd ~ 0.2 nM |      |      |       |             |        |        |
| Bₘₐₓ ~9,600 sites/cell |      |      |       |             |        |        |
| [³H]-LXA₄ |      |      |       |             |        |        |
| IC₅₀ < 0.1 nM with LXA₄ |      |      |       |             |        |        |
| IC₅₀ ~ 1 nM with peptides |      |      |       |             |        |        |

ALXR (bold)/BLTR (regular) chimeras were constructed and ligand binding assay was carried out as described in Materials and Methods. Nonspecific binding was determined in the presence of 100 nM of unlabeled homoligand. NSB, no specific binding with 1 nM of radioligands (e.g., [³H]-LXA₄ or [³H]-LTB₄).
at <1 nM (EC₅₀ for analogues ~ 8 × 10⁻¹¹ M, EC₅₀ for LX₄₂ ~ 8 × 10⁻¹⁰ M) (33) and inhibit PMN transmigration and adhesion at levels as low as 10⁻¹⁰ M (27) by evoking cell type–specific intracellular signaling responses. It is noteworthy that LX and ATL analogue activation of ALXR does not appear to involve either cAMP (not shown) or the mobilization of appreciable levels of intracellular Ca²⁺ in either monocytes or neutrophils to mount functional responses (27, 33). On the other hand, MMK-1 stimulates intracellular Ca²⁺ mobilization (28) and increases extracellular acidification rates in a receptor-dependent fashion (Fig. 3). Although intracellular Ca²⁺ mobilization accompanies many leukocyte responses (1, 2), its role in chemotaxis remains controversial in human peripheral blood neutrophils and monocytes (44).

Since LXs activate monocytes and inhibit PMNs (in both murine and human cells; references 16, 33), it is likely that LXs are mediators of resolution (45) where it is well appreciated that monocyte recruitment plays a pivotal role in wound healing (1). Hence, our results here emphasize the importance of both temporal and local ligand-initiated signal transduction. In this context, with PMNs, ALXR interaction with LX and ATL analogues regulates a newly described polyisoprenyl phosphate signaling pathway. ALXR activation reverses leukotriene B₄-initiated polyisoprenyl phosphate remodeling, leading to accumulation of presqualene diposphosphate, a potent negative intracellular signal in PMNs that inhibits recombinant phospholipase D and superoxide anion generation (46). The complete intracellular signal transduction pathways initiated after ALXR interaction with ATL and LX are the subject of ongoing efforts, and the novel chimeric receptors reported here open new avenues to examine intracellular signals that are directly dependent on peptide versus lipid ligands.

Our results demonstrate for the first time via direct evidence that bioactive lipids as well as certain selective small peptides/proteins can each serve as ligands at the same G protein–coupled receptor, namely ALXR, but clearly act with different affinity and/or distinct interaction sites within the ALXR. It appears likely that the G protein interactions evoked by ligand–receptor binding and their intracellular amplification mechanisms are different for peptide versus lipid ligands of ALXR, and hence they can dictate different functional response in vivo. Also, these results provide new evidence for the diversity of host recognition by PMNs and place these ligand-initiated responses as a "when and where" activity of PMNs or monocytes in acute defense and wound healing (see reference 45). However, our data clearly indicating that ALXR

Figure 8. The seventh transmembrane segment and third extracellular loop of human ALXR are essential for LX₄₂ and peptide recognition: BLT/ALXR chimeras (A) Sequences of human ALXR (bold type), BLT (regular type), and B/A₂₅₄ chimera at sixth transmembrane, third extracellular loop, and seventh transmembrane. Inset shows e₁–e₃, representing the putative extracellular loops TMI–VII, the transmembrane segments and i₁–i₃, intracellular loops for ALXR (bold line) or BLT (regular line). (B) ALXR-, BLT-, or B/A₂₅₄-transfected HEK293 cells (5 × 10⁵/ml) were incubated with ³H-LX₄₂ (1 nM, black bar) or ³H-LTB₄ (1 nM, white bar) in the absence or presence of 100 nM of unlabeled homoligand. (C) B/A₂₅₄-transfected HEK293 cells were incubated with ³H-LX₄₂ (1 nM) in the presence of an increasing concentration of unlabeled LX₄₂ (■), MMK-1 (△), or MHC binding peptide (○) for 30 min at 4°C. Bound and unbound radioligands were separated by filtration and specific binding was determined. Data represent the mean ± SEM from n = 3.
is responsible for LX A 4 's regulatory actions in leukocytes do not preclude the involvement of additional plasma membrane receptors and/or intracellular targets in LX A 4 signal transduction. In addition to specific binding to membrane surface receptors, we found that specific binding of labeled LX A 4 was associated with subcellular fractions including granules and nucleus (40). Along these lines, it was recently reported that LX A 4 binds to and activates the aryl hydrocarbon receptor, a ligand-activated transcription factor, in a murine hepatoma cell line (47). It is of interest in view of the present results that aryl hydrocarbon receptor-deficient mice showed decreased accumulation of lymphocytes in the spleen and lymph nodes, suggesting an important role for aryl hydrocarbon receptor in the immune system (48).

In summary, we identified the first endogenous non-LX ligand for ALXR, namely MHC binding peptide, and show that both the MHC binding peptide and surrogate peptide MMK-1 evoked potential proinflammatory signals, whereas the endogenous lipid LX A 4 gave antiinflammatory signals in vivo, yet they interact via the same G protein-coupled receptor (49). This indicates that LX A 4 's regulatory actions in leukocytes is of interest in view of the present results that aryl hydrocarbon receptor, in a murine hepatoma cell line (47). It is of interest in view of the present results that

References

1. Cotran, R.S. 1999. Inflammation: historical perspectives. In Inflammation: Basic Principles and Clinical Correlates, 3rd ed. J.I. Gallin, R. Snyderman, D.T. Fearon, B.F. Haynes, and C. Nathan, editors. Lippincott Williams & Wilkins, Philadelphia. 5–10.
2. Weissmann, G., J.E. Smolen, and H.M. Korchak. 1980. Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 303:27–34.
3. Samuelsson, B. 1982. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. T. Frängsmry, editor. Almqvist & Wiksel, Stockholm. 153–174.
4. Yokomizo, T., T. Izumi, K. Chang, Y. Takuma, and T. Shimizu. 1997. A G-protein-coupled receptor for leukotriene B 4 that mediates chemotaxis. Nature. 387:620–624.
5. Perez, H.D. 1994. Chemoattractant receptors. Curr. Opin. Hematol. 1:40–44.
6. Pillinger, M.H., and S.B. Abramson. 1995. The neutrophil in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21:691–714.
7. Serhan, C.N., J.Z. Haeggstrom, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147–1158.
8. Diamond, P., A. McGinty, S. Sugrue, H.R. Brady, and C. Godson. 1999. Regulation of leukocyte trafficking by lipoxins. Clin. Chem. 37:293–297.
9. N ode, K., Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D.C. Zeldin, and J.K. Liao. 1999. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285:1276–1279.
10. Munger, K.A., A. Montoero, M. Fukunaga, S. Uda, T. Yura, E. Imai, Y. Kaneda, J.M. Valdivielso, and K.F. Badr. 1999. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. U.S.A. 96:13375–13380.
11. Wissmann, G., 1991. Aspirin. Scand. J. 264:84–90.
12. M arcus, A.J. 1995. Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333:656–658.
13. T akano, T., S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petais, and C.N. Serhan. 1997. Aspirin-triggered 15-epi-lipoxin A 4 (LXA 4 ) and LXA 4 stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185:1693–1704.
14. C lish, C.B., J.A. O’Brien, K. Gronert, G.L. Stahl, N.A. Petais, and C.N. Serhan. 1999. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U.S.A. 96:8247–8252.
15. C hiang, N., K. Gronert, C.B. Clish, J.A. O’Brien, M.W. Freeman, and C.N. Serhan. 1999. Leukotriene B 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104:309–316.
16. Hachicha, M., M. Pouliot, N.A. Petais, and C.N. Serhan. 1999. Lipoxin (LX) A 4 and aspirin-triggered 15-epi-lipoxin A 4 inhibit tumor necrosis factor-α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189:1923–1929.
17. Fiore, S., J.F. Maddox, H.D. Perez, and C.N. Serhan. 1994. Identification of a human cDNA encoding a functional high affinity lipoxin A 4 receptor. J. Exp. Med. 180:253–260.
18. Fiore, S., and C.N. Serhan. 1995. Lipoxin A 4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD 11/18 expression by lipoxin A 4 lipoxin A 4 receptor interaction. Biochemistry. 34:16678–16686.
19. Quenemberger, O., E.R. Prossnitz, S.L. Cavanagh, C.G. Cochran, and R.D. Ye. 1993. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide re-
25. Wang, C.R., A.R. Castano, P.A. Peterson, C. Slaughter, M.R. Jackson, W.D. Huse, M. Kronenberg, and P.A. Peterson. 1995. Peptide binding and presentation by mouse CD1. Science. 269:223–226.

26. Shawar, S.M., R.R. Rich, and E.L. Becker. 1995. Peptides and covalent modification of formylated peptide in crystal structure of the MHC class Ib molecule H-2-M3. Cell. 82:655–664.

27. Serhan, C.N., J.F. Maddox, N.A. Petasis, I. Akritopoulou-Nestoridou, S.T. Furlong, and M.B. Brenner. 1994. Recognition of a lipid antigen by CD1-restricted αβ T cells. Nature. 372:691–694.

28. Klein, C., J.I. Paul, K. Sauve, M.M. Schmidt, L. Arcangeli, J.K. Fokin, and C.N. Serhan. 1997. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272:6972–6978.

29. Tessier, P.A., P.H. Naccache, I. Clark-Lewis, R.P. Gladue, M.R. Jackson, W.D. Huse, M. Kronenberg, and P.A. Peterson. 1995. Lipoxin A4 stimulates hepatic fibrosis in mice lacking the dioxin-binding receptor. Science. 268:18167–18175.

30. Castano, A.R., S. Tangri, J.E. Miller, H.R. Holcombe, T. Furlong, and M.B. Brenner. 1994. Recognition of a lipid antigen by CD1-restricted αβ T cells. Nature. 372:691–694.

31. Brezinski, D.A., and C.N. Serhan. 1991. Characterization of lipoxins by combined gas chromatography and electron-capture negative ion chemical ionization mass spectrometry: formation of lipoxin A4 by stimulated human whole blood. Biol. Mass Spectrom. 20:45–52.

32. Falk, W., R.H. Goodwin, and E. Leonard. 1980. A 48-well microchemotaxis assembly for rapid and accurate measurement of leukocyte migration. J. Immunol. Methods. 33:239–247.

33. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and the acute-phase response. N. Engl. J. Med. 340:448–454.

34. Villanueva, M.S., C.J. Becker, and E.G. Pamer. 1994. Infection with Listeria monocytogenes impairs asialic acid addition to host cell glycoproteins. J. Exp. Med. 180:2137–2145.

35. Olofsson, S., B. Khanna, and E. Lycke. 1980. Altered kinetic properties of sialyl and galactosyl transferases associated with herpes simplex virus infection of GMK and BHK cells. J. Gen. Virol. 47:1–9.

36. Schaldach, C.M., J. Riby, and L.F. Bjeldanes. 1999. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry. 38:7594–7600.